若生智能
Drug Database
DO

doxycycline (Perio Product / Atridox / doxycycline, Atrix)

✓ Approved

Pharmascience, Inc. · 小分子 · 小分子

什么是 doxycycline？

doxycycline 是一种小分子，由Pharmascience, Inc.研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)、Topical。

药物档案

商品名Perio Product, Atridox, doxycycline, Atrix
公司Pharmascience, Inc.
药物类别小分子
给药途径Oral (PO), Topical
状态Approved
来源： ClinicalTrials.gov, Pharmascience, Inc.

治疗适应症

doxycycline 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsPeriodontitis✓ Approved

相关研究文献

PubMedBiochemical and biophysical research communications2026-06-13

Constitutively active MEK1 expression driven by the myeloid-selective MRP8 promoter induces epithelial hyperplasia and papilloma formation.

Zang Yan Y, Duan Ranhui R, Miranda Michelle B MB, Rigatti Lora H LH et al.

The mitogen-activated protein kinase kinase (MEK)/extracellular-regulated kinase (ERK) signaling pathway is hyperactivated in myeloid leukemias characterized by differentiation blockade, suggesting a potential role in disruption of myeloid differentiation. However, other reports indicate that MEK/ERK activation is required for normal myeloid differentiation. To investigate the in vivo role of MEK/ERK hyperactivation in myeloid differentiation and leukemia development we generated transgenic mice with doxycycline (DOX)-inducible expression of constitutively active MEK1 (CA-MEK1) under the control of the myeloid-selective MRP8 promoter. Two independent transgenic lines (lines A and B) were generated. Strikingly, both lines developed epithelial abnormalities following DOX induction of CA-MEK1. Line A mice exhibited pervasive skin/epithelial thickening, while line B mice developed papillomas. Prominent induction of CA-MEK1 was detected in epidermis, but not dermis, and was accompanied by epithelial cell hyperplasia. Line B mice also exhibited CA-MEK1 induction and ERK1/2 phosphorylation/activation in bone marrow and blood. Induction of CA-MEK1 over a range of 8-33 weeks, however, failed to alter the frequency of monocytes and granulocytes in the blood of line B mice. Collectively, our findings demonstrate that the MRP8 promoter is active in both myeloid and epithelial tissues. Moreover, we confirm earlier reports that hyperactivation of MEK/ERK signaling in epithelial tissues promotes epithelial hyperplasia. In addition, our findings indicate that hyperactivation of the MEK/ERK pathway alone is insufficient to alter myeloid differentiation and initiate leukemia development. We propose that MEK/ERK hyperactivation likely acts to promote proliferation or cell survival in leukemias where differentiation has been blocked by other genetic or epigenetic events.

PMID 42284988
阅读全文 →
PubMedActa pharmacologica Sinica2026-06-13

Sevoflurane-induced disruption of critical period Arc signaling drives aberrant microglial synaptic pruning and cognitive deficits.

Chen Bai-Hui BH, Chen Ye-Ru YR, Zheng Liang-Yu LY, Cai Hua-Jing HJ et al.

Early-life sevoflurane exposure is associated with long-term cognitive deficits. Given that hippocampal development relies on precise critical windows, disruption of developmental processes during these periods is likely the origin of these impairments. However, the molecular mechanisms underlying sevoflurane-induced perturbations during critical development periods and their progression to lasting cognitive dysfunction remain elusive. Here, we determined that the first three postnatal weeks are a critical window of vulnerability to early-life sevoflurane exposure. Mechanistically, sevoflurane exposure suppressed the physiological upregulation of activity-regulated cytoskeleton-associated protein (Arc; also known as Arg3.1) during the critical period of hippocampal development, a process driven by glycogen synthase kinase-3 beta (GSK3β)-mediated protein degradation. We demonstrated that transient suppression of Arc via hippocampal injection of Arc antisense oligonucleotide (ASO) during the third postnatal week was sufficient to recapitulate the sevoflurane-induced phenotype, impairing microglial synaptic pruning and causing initial synaptic redundancy. This early pathology subsequently evolved into aberrant microglial phagocytic activation in adolescence and adulthood, resulting in excessive synaptic loss and cognitive deficits. Crucially, restoration of Arc expression specifically during this critical period using a doxycycline (Dox)-inducible Tet-On system successfully reversed this pathological pruning trajectory and prevented long-term cognitive impairment. Our findings highlight that Arc upregulation during this critical period is essential for microglial function and synaptic homeostasis, establishing Arc as a time-sensitive therapeutic target for preventing the developmental neurotoxicity associated with pediatric anesthesia. This diagram illustrates the role of the Arc protein in microglial synaptic pruning and cognitive development under physiological conditions (upper panel, blue; Arc is highly expressed during the critical period) and sevoflurane exposure (lower panel, red; Arc expression during the critical period is downregulated). Under normal conditions, Arc is expressed during the critical period and is localized to synapses, where it facilitates the tagging of redundant synapses for elimination. Synaptic pruning peaks during the critical period, followed by further refinement during adolescence, leading to mature cognitive function in adulthood. Neonatal sevoflurane exposure leads to aberrant activation of GSK3β during the critical period. This promotes Arc degradation, thereby disrupting its synaptic localization. This leads to microglial dysfunction in terms of synaptic engulfment. In adolescence, this disruption leads to excessive microglial phagocytosis and significant synaptic loss, ultimately resulting in cognitive deficits. Graphical elements: GSK3β, green circles; Arc, orange circles; phosphorylation site, pale yellow circle containing the letter "P"; C1q, yellow umbrella shapes.

PMID 42286336
阅读全文 →
PubMedCureus2026-06-12

Recurrent Red Eye Misdiagnosed as Conjunctivitis: Ocular Rosacea With Corneal Neovascularization in a Young Patient.

Ferreira Joana J, Embalo Aissatu A, Rodrigues Ana A, Cavaco Sonia S et al.

Chronic red eye is a prevalent presentation in both primary care and emergency settings. While most cases are self-limiting, recurrent or treatment-resistant episodes warrant systematic evaluation to exclude underlying chronic inflammatory conditions. We report the case of a 19-year-old female patient with a longstanding history of bilateral red eye associated with pain, photophobia, and epiphora, initially and repeatedly managed as infectious conjunctivitis in the emergency department (ED). Despite multiple antibiotic courses, symptoms persisted. Ophthalmologic evaluation ultimately revealed chronic anterior and posterior blepharitis with meibomian gland dysfunction, peripheral corneal infiltrates, and neovascularization (NV) - findings consistent with ocular rosacea. Notably, subtle cutaneous signs of rosacea were also identified on clinical examination, further supporting the diagnosis. Following targeted therapy with oral doxycycline 100 mg twice daily, topical corticosteroids (CSs), and ocular lubricants, the patient achieved significant clinical improvement. This case highlights the diagnostic pitfalls of recurrent red eye in primary care, the importance of recognizing chronic inflammatory ocular surface disease, and the value of timely ophthalmologic referral in preventing irreversible corneal complications.

PMID 42281673
阅读全文 →
PubMedJournal of the American Association of Nurse Practitioners2026-06-12

Increasing the evaluation of Mycoplasma and Ureaplasma infections in primary care: A quality improvement project.

Volpert Elisabeth Marie EM, Corniel Brittney B, Croghan Aubree A, Humphreys Melissa M et al.

Mycoplasma and Ureaplasma infections are frequently underdiagnosed and undertreated in primary care, contributing to adverse reproductive and genitourinary outcomes. Limited routine screening, diagnostic complexity, and variable provider awareness contribute to gaps in care. In an academic primary care setting, patients presenting with genitourinary symptoms were infrequently evaluated for Mycoplasma and Ureaplasma. This quality improvement project was conducted in two academic family medicine clinics. Pre- and postintervention retrospective chart reviews assessed rates of testing and diagnosis among adult patients presenting with urethral or vaginal discharge, pelvic pain, and/or dysuria. Provider education and standardized evaluation and treatment algorithms were implemented. An educational session was delivered and supported with emailed materials. Standardized algorithms outlining indications for testing and recommended treatments were integrated into clinical workflow. During the study period, 519 patients presented with genitourinary symptoms. Recurrent symptoms consistent with Mycoplasma or Ureaplasma infection were identified in 205 patients (39.5%); however, 133 (64.9%) were not screened. Among the 72 patients (35.1%) who underwent diagnostic testing, 46 (63.9%) tested positive. Overall, 45 patients were diagnosed with Mycoplasma or Ureaplasma infections, including Mycoplasma hominis (26.7%), Ureaplasma parvum (31.1%), Ureaplasma urealyticum (20.0%), and Mycoplasma genitalium (20.0%). Most patients received guideline-concordant antimicrobial therapy, primarily doxycycline, azithromycin, or levofloxacin, with referral for specialty evaluation in cases of persistent infection. These primary care-based interventions reduced underdiagnosis and improved reproductive and genitourinary health outcomes. Targeted provider education and streamlined diagnostic protocols improved evaluation and screening for Mycoplasma and Ureaplasma in primary care.

PMID 42283401
阅读全文 →
PubMedAnalytical and bioanalytical chemistry2026-06-12

Development of a capsule phase microextraction (CPME) protocol for the determination of four tetracyclines in human urine prior to HPLC-DAD analysis.

Vasileiou Fedra F, Antos Joanna J, Gkouma Maria M, Voutsas Pavlos P et al.

In this work, a novel and green capsule phase microextraction method followed by high-pressure liquid chromatography coupled to diode array detector (CPME-HPLC-DAD) was developed for the selective determination of four tetracyclines, namely oxytetracycline (OTC), tetracycline (TC), chlortetracycline (CTC) and doxycycline (DC), in human urine. Among five tested CPME devices, the sol-gel C18 capsules exhibited the highest extraction efficiency. The main factors affecting the sample preparation procedure were optimized using the one-factor-at-a-time (OFAT) strategy, leading to the selection of 4 mL as the optimal sample volume. Following the optimization of CPME parameters, the method was validated in terms of linearity, selectivity, accuracy, sensitivity and precision. For all analytes, linearity was confirmed over the concentration range of 0.03-0.50 μg/mL (R2 > 0.998), while method limits of detection (LODs) and quantification (LOQs) were equal to 9 ng/mL and 30 ng/mL, respectively. The relative standard deviation (%RSD) expressing intra-day and inter-day repeatability of the reported method were found to be lower than 6.7% and 8.7%, respectively. The accuracy of the optimized method was evaluated using spiked samples with analytical recoveries ranging from 93.9% to 110.8% (intra-day) and 90.8% to 112.4% (inter-day). The green character and practicality of the proposed method, as well as the level of innovation and analytical performance were assessed using advanced metric tools, including ComplexMoGAPI (Complex Modified Green Analytical Procedure Index), BAGI (Blue Applicability Grade Index), VIGI (Violet Innovative Grade Index) and RAPI (Red Analytical Performance Index). Overall, the developed CPME-HPLC-DAD protocol provides a simple, eco-friendly and highly reliable approach for the selective quantification of these four tetracyclines in human urine.

PMID 42283807
阅读全文 →
PubMedNaunyn-Schmiedeberg's archives of pharmacology2026-06-11

Repurposing doxycycline as an adjunct to sitagliptin in type 2 diabetes mellitus: a randomized controlled study on glycemic, inflammatory, and cardiometabolic outcomes.

El-Khateeb Eman E, Khrieba Mohannad O MO, Badawoud Amal Mohammad AM, Morsy Ahmed A AA et al.

Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance, β-cell dysfunction, and chronic low-grade inflammation. Doxycycline exhibits anti-inflammatory properties, suggesting potential benefit as an adjunctive therapy in T2DM. To evaluate the efficacy and safety of adjunctive doxycycline in patients with T2DM receiving sitagliptin. In this randomized controlled trial, 57 patients with T2DM were assigned to receive sitagliptin alone (n = 29) or sitagliptin plus doxycycline (n = 28) for 12 weeks. Glycemic indices, insulin sensitivity measures, lipid profile, cardiometabolic risk indices, and inflammatory markers were assessed before and after treatment. Parametric outcomes were analyzed using analysis of covariance (ANCOVA) adjusted for baseline values, while non-parametric biomarkers were analyzed using Hodges-Lehmann estimators. Multivariable linear regression identified independent determinant of treatment response. Between-group comparisons for secondary outcomes were adjusted using the Benjamini-Hochberg false discovery rate. Both groups showed significant within-group improvements in body weight, glycemic indices, lipid profile, and inflammatory markers (p < 0.05). However, the combination therapy demonstrated superior outcomes. Significant reductions were observed in fasting blood glucose (adjusted mean difference: - 6.20 mg/dL, p = 0.034), fasting insulin (- 2.02 μIU/mL, p = 0.008), HOMA-IR (- 0.83, p < 0.001), and HbA1c (- 1.25%, p < 0.001), along with increased insulin sensitivity (QUICKI: + 0.0086, p < 0.001). Cardiometabolic parameters were also significantly improved, including total cholesterol (- 14.0 mg/dL, p = 0.030), triglycerides (- 11.6 mg/dL, p = 0.007), LDL-C (- 14.4 mg/dL, p < 0.001), and HDL-C (+ 4.8 mg/dL, p = 0.030). Risk indices (AI, CVRI, CRR) showed marked reductions (all p < 0.05). Inflammatory biomarkers were associated with improvements with combination therapy, including reductions in MMP-9 (p = 0.030) and CRP (p = 0.002). Regression analysis identified doxycycline treatment as an independent determinant of improvement in most outcomes, including HbA1c, HOMA-IR, QUICKI, lipid indices, and MMP-9. FDR correction confirmed the robustness of these findings. Correlation analyses revealed strong associations between insulin resistance markers and cardiometabolic indices. Adverse events were mild and comparable between groups. The addition of doxycycline to sitagliptin appears to improve glycemic control, insulin sensitivity, cardiometabolic risk profile, and inflammatory status in T2DM, without increasing adverse effects. These findings are exploratory and should be confirmed in larger trials with longer follow-up. CLINICAL TRIAL IDENTIFIER: NCT06329882.

PMID 42271067
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多doxycycline